Key PointsSpecial Supplemental Benefits for the Chronically Ill (SSBCI) affects Medicare enrollees with chronic medical conditions.Services under this expansion should improve or m

Key PointsChewy stock is down 70% in the past five years.The pet supplier consistently ranks high in customer satisfaction and loyalty.Chewy's Autoship program accounts for 84% of

TradingKey - Taiwan Semiconductor Manufacturing Co. (TSM) Latest quarterly financial results show that, driven by strong demand for AI hardware, the company's profit grew significantly, substantially

Key PointsAlthough you're allowed to work while receiving Social Security, in some cases, your income could result in withheld benefits.You only have to worry about that if you hav

Key PointsArtificial intelligence is already a meaningful contributor to economic growth, and the market is projected to expand at 31% annually through 2033.CoreWeave is the leader

Key PointsWalmart will be admitted to the Nasdaq-100 this month after moving its listing in December.The company's market-leading position, market share gains, and adoption of tech

Key PointsData center spending could climb to $7 trillion by 2030, according to McKinsey.Advanced Micro Devices expects revenue to grow at a 35% compound annual rate over the next

Key PointsAlphabet and Microsoft each operate massive cloud computing operations.Nvidia will need to replace worn GPUs on a regular basis.Taiwan Semiconductor Manufacturing is work

Key PointsTJX has the opportunity to grow its store base by around 35% over the long term.The off-price model benefits when traditional retailers struggle, driving impressive sales

TradingKey - In the year 2025, Nebius Group (NBIS) has experienced an incredible ride, with its stock price increasing about 200% during this time period (after jumping more than threefold since this

Key PointsIn a few weeks, 13-F filings will reveal the last moves that Warren Buffett made in his tenure as Berkshire Hathaway's CEO. He has bought silver twice before, most recent

Key PointsIonQ is one of the most popular quantum computing stocks.The company has given the appearance of rapid growth thanks to a series of acquisitions.IonQ is trading at a hist

Key PointsAlphabet's core advertising business remains a juggernaut.Google Cloud's momentum appears to be unstoppable.Alphabet also has multiple other ways to grow.10 stocks we lik

January 14, 2026 — WuXi XDC has issued a positive profit alert for fiscal 2025 and announced a cash tender offer for BioDlink, whose shares were suspended from trading at 9am on December 29 pending details of the bid.The alert underscores the ADC CRDMO leader’s strong performance: it forecasts 45% year-on-year revenue growth in 2025, alongside over 70% gross profit growth and more than 45% growth in adjusted net profit (excluding interest income and expenses). Stripping out exchange rate fluctuations, adjusted net profit growth is projected to hit 65%.A pioneer in the ADC CRDMO space, WuXi XDC has driven synergistic growth through organic expansion and strategic acquisitions amid strong business momentum. The BioDlink acquisition will boost its operational capacity in China, expand production scale, enhance support for biotech firms via value-added services, broaden its project portfolio and customer base, and reinforce its leading position in the ADC CDMO sector."Capital for time": WuXi XDC targets CDMO capacity bottlenecksThe bioconjugate drug industry has reached a commercial inflection point as clinical pipelines expand, widening the capacity gap. Public data shows 21 ADC drugs had been approved globally by end-December 2025. Emerging classes such as AOCs, RDCs and PDCs are advancing rapidly with robust late-stage pipelines, emerging as new growth drivers in biopharma.Against accelerating global bioconjugate commercialisation, insufficient capacity has become a major constraint for CDMOs. Rapid pipeline expansion and upcoming commercial demand have made "capacity delivery capability" a core competitive advantage and key metric for investors assessing CDMO growth potential.For leading CDMOs, the approach to resolving capacity bottlenecks directly shapes market influence. Building new production lines—from site selection and construction to certification—typically takes three to five years, too slow to keep pace with surging bioconjugate commercial demand. WuXi XDC’s proactive strategy of acquiring existing facilities, using efficient capital operations to capture market opportunities, stands out as optimal in the sector. The BioDlink deal aligns with this logic, enabling rapid capacity expansion via external integration and ensuring steady performance growth.Building on strengths: Tech platforms and talent drive growthWuXi XDC leads the industry with advanced conjugation and payload-linker technologies, and extensive bioconjugate drug development experience. It has rolled out innovative platforms including WuXiDARx™, dual-payload conjugation, X-LinC linker, and WuXiTecan-1/2 payload-linker technologies.To meet global customers’ diverse ordering needs and complex R&D requirements, it adopts a two-pronged "independent R&D plus external collaboration" strategy to build an integrated technology platform. This enriches technical reserves, boosts front-end R&D pipeline generation, and strengthens its R&D leadership.Talent is critical to the bioconjugate CDMO sector, but rapid industry growth has outpaced professional talent supply, a key growth constraint. WuXi XDC has long prioritised talent development; its workforce exceeded 2,600 by end-2025. The expanded professional team has formed a talent cluster, underpinning long-term growth.Riding the wave: WuXi XDC’s global capacity pushData from PharmaCube’s NextPharma shows China’s innovative drug overseas licensing transactions hit $135.655bn in 2025, including $7bn in upfront payments across 157 deals—far outstripping 2024’s $51.9bn and 94 transactions. Overseas licensing has seen explosive growth, with upfront payments and total volume at record highs. As a key bioconjugate segment, ADCs are a focus for global capital. WuXi XDC has delivered standout performance here, with steady post-listing revenue growth underscoring both the bioconjugate CDMO track’s potential and the company’s core competitiveness.Sustained business growth has made capacity expansion a key driver of high growth. By end-December 2025, WuXi XDC had worked with over 640 global customers on 252 iCMC projects. It also holds 18 PPQ projects and one commercial project, with nearly 1,000 production batches of drug substance (DS) and drug product (DP). These figures highlight strong market expansion and capacity deployment, reflecting robust demand for its services.The industry’s capacity shortage is both quantitative and structural, marked by a lack of "high-quality, integrated" capacity. Hundreds of ADCs globally are in active clinical phases, creating strong demand for commercial capacity. Meanwhile, bioconjugates’ complex production processes, high industry barriers and long supply chains have further widened the gap.Against this backdrop, WuXi XDC has established capacity in Wuxi, Jiangyin, Hefei (China) and Singapore. This global network meets global customers’ local production needs, improves operational efficiency via coordinated capacity allocation, strengthens its bioconjugate CDMO lead, and allows it to fully capture industry growth opportunities.Table: WuXi XDC’s capacity layout as of end-2025 Layout Capacity Wuxi Site XBCM1(Conjugation DS):5-500L per batch XBCM2 L1&L2(Dual-function lines for antibody and conjugation DS): 50L to 2000L per batch for monoclonal antibody intermediates orup to 2000L of DS per batch Conjugation DP Lines: XDP1:annual capacity of 3 million vials XDP2:annual capacity of 5 million vials XDP3:annual capacity of 7 million vials XDP5:annual capacity of 12 million vials, expected to GMP release in 2027 XDP6:annual capacity of 10 million vials, expected to GMP release by late 2027 / early 2028 XPLM1(Kilogram-scale payload-linker Line, business from former Changzhou site is being gradually transferred to Wuxi site) Singapore Site XBCM3(Dual-function line for antibody and conjugation DS): 50L to 2000L per batch for monoclonal antibody intermediates orup to 2000L of DS per batch, expected to GMP release in 2026 XBCM4(Conjugation DS):up to 500L per batch, expected to GMP release in 2026 XDP4(Conjugation DP):annual capacity of 8 million vials, expected to be operational in 2026 Jiangyin Site Integrated Commercial Manufacturing Site:serves as a nearby expansion for Wuxi site, including large-scale commercial small molecule production and conjugation production workshops. Hefei Site Non-GMP Manufacturing:Peptide annual capacity of ~600 batches, ~30kg GMP Manufacturing:Peptide annual capacity of ~200 batches, ~10kg Data source: Company filingsWuXi XDC to sustain capacity expansion driveLooking ahead, WuXi XDC will continue to advance overseas capacity expansion steadily and proactively, further entrenching its global leadership in the bioconjugate CDMO sector.In September 2025, the company completed a $350m refinancing, leveraging strong performance and industry reputation. Combined with a previous $200m credit facility and operational reserves, it has built a sufficient capital pool to support global capacity expansion.Backed by solid capital and mature expansion experience, WuXi XDC will pursue overseas capacity growth at an "active yet prudent" pace. It is evaluating global expansion opportunities to optimise its production network—moves that will enable local delivery, deepen penetration in the global bioconjugate CDMO sector, and reinforce its industry lead.OutlookWuXi XDC’s accelerated capacity deployment mirrors the rapid growth of ADC and other bioconjugate industries, driving the CDMO sector into a golden growth period. Frost & Sullivan data shows the global ADC drug market reached $17.2bn in 2025, with a 30.6% compound annual growth rate (CAGR) from 2023 to 2032, and is set to exceed $115.1bn by 2032. The global ADC outsourcing market is also growing strongly, projected to hit $11bn by 2030 with a 28.4% CAGR from 2022 to 2030. High growth in both sectors offers ample room for CDMO expansion.Capacity shortages are a phased challenge in the booming bioconjugate CDMO industry, unlikely to be fully resolved short-term. Over the medium to long term, however, new capacity from leading players and rising industry concentration will ease the supply-demand imbalance. WuXi XDC’s early focus on "acquisition plus expansion"—backed by accurate industry trend judgment—has secured its edge in current capacity competition and positioned it to dominate the future bioconjugate CDMO landscape, leveraging strengths in capacity scale, technical barriers and global reach.Sources1. Hong Kong Exchanges and Clearing (HKEX)2. WuXi XDC3. Frost & Sullivan4. PharmaCube5. Insight Database6. WuXi XDC presentation, 2025 Jefferies London Healthcare Conference15/01/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Key PointsVCIT is substantially cheaper to own than FBND, but FBND holds a wider mix of bonds and a lower five-year drawdownFBND carries a marginally higher yield and much lower be

Key PointsU.S. EV sales were down for 2025, creating rough headwinds for EV manufacturers. Rivian and Lucid are on shaky ground with their high losses and relatively low sales volu

Key PointsPrecious metals like gold and silver are gaining in value rapidly. That hasn't translated into a rapid climb for Bitcoin or Zcash.But it might still happen, and soon. 10

Key PointsNvidia is still growing at an incredible pace, but the stock is priced for near perfection.Alphabet is showing broad-based growth and improving profitability in Google Cl

Key PointsSMH gives investors direct exposure to the entire AI-powered semiconductor value chain. The ETF has a long history of solid returns.Increasing inference workloads have fu

Key PointsAI stocks were some of the biggest winners in 2025, but that doesn't mean there isn't upside remaining.The next leg of the AI rally might come from stocks outside the "Ma

Key PointsRegulatory clarity and inflows in ETFs have improved XRP’s near-term demand dynamics.However, XRP’s role in facilitating fast and efficient cross-border payments reduces

Key PointsCoca-Cola is on track to increase its dividend for a 64th straight year. The company’s durable pricing power supports high profits and free cash flow.Despite the compelli

Key PointsNvidia is the dominant player in AI infrastructure, but it is starting to face more competition.Broadcom is increasingly becoming the company others turn to in order to h

Key PointsTwo analysts published optimistic new takes on the specialized AI solutions developer. One raised his price target on its shares.10 stocks we like better than Rezolve Ai

Key PointsNvidia has become the world's largest company following its surge in recent years.The company still has a substantial addressable market that could drive its long-term gr

Explore the exciting world of Qualcomm (NASDAQ: QCOM) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insig

Key PointsThe prominent bank unveiled its fourth quarter of 2025 results.These were mixed, as the company beat on earnings but whiffed on revenue.10 stocks we like better than Well

Key PointsBoredom can be a major problem for retirees.If you need things to do, consider getting a job or volunteering.Learning new things might improve your outlook, as might expa

Key PointsNvidia is the leading seller of chips powering the high-growth field of AI.This has led to record revenue and a soaring stock price. 10 stocks we like better than Nvidia

Key PointsA top-down analysis of the U.S. chemical sector is predicting notable growth over the next few years.It is expected to expand by 36% between last year and 2033.10 stocks